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Abstract: Several anti-inflammatory agents based on pyrazole and imidazopyrazole scaffolds and a
large library of substituted catechol PDE4D inhibitors were reported by us in the recent past. To obtain
new molecules potentially able to act on different targets involved in inflammation onset we designed
and synthesized a series of hybrid compounds by linking pyrazole and imidazo-pyrazole scaffolds to
differently decorated catechol moieties through an acylhydrazone chain. Some compounds showed
antioxidant activity, inhibiting reactive oxygen species (ROS) elevation in neutrophils, and a good
inhibition of phosphodiesterases type 4D and, particularly, type 4B, the isoform most involved in
inflammation. In addition, most compounds inhibited ROS production also in platelets, confirming
their ability to exert an antiinflammatory response by two independent mechanism. Structure–activity
relationship (SAR) analyses evidenced that both heterocyclic scaffolds (pyrazole and imidazopyrazole)
and the substituted catechol moiety were determinant for the pharmacodynamic properties, even if
hybrid molecules bearing to the pyrazole series were more active than the imidazopyrazole ones.
In addition, the pivotal role of the catechol substituents has been analyzed. In conclusion the
hybridization approach gave a new serie of multitarget antiinflammatory compounds, characterized
by a strong antioxidant activity in different biological targets.
Keywords: pyrazole-4-carbohydrazides; imidazopyrazole-7-carbohydrazides; reactive oxygen
production inhibition; platelets; neutrophils; phosphodiesterase inhibitors
1. Introduction
Inflammation is a very complex response of mammals’ body to different external injuries, including
traumatic events, contact with irritant substances, pathogens invasion and more. There are different
stages in inflammation evolution: the acute phase includes the movement of leukocytes from the
blood vessel to the tissues and the immune system activation, aiming to damage control. Then, the
prolongation of this initially protective response can lead to a state of chronic inflammation that is
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characterized by the intervention of other type of cells (such as macrophages and lymphocytes) and
injured tissues destruction. Several pathologies are caused by chronic inflammation.
Neurodegenerative disorders are typically multi-factorial diseases. Neuroinflammation is one
among the different pathological alteration responsible for their onset and, as other multi-target
pathologies, is difficult to treat by a mono-therapy. To get around this problem a new medicinal
chemistry paradigm suggests the use of multi-targeted compounds, single small molecules able to
act with different mechanism of action against two or more target [1,2]. Polypharmacology with
multitarget compounds looks like a winner strategy as it retains the advantages of the multi-drugs
therapy without the toxicity and compliance problems related to the use of more than one molecule in
combination. Since there are different cellular pathways involved in inflammation progression, and
also in neuroinflammation, a multi-target molecules could be very useful in several pathologies such
as Alzheimer’s disease (AD) or multiple sclerosis (MS).
A multi-target compound can be designed by combining two different molecules (obtaining
“chimera” compound) or by overlapping two pharmacophore fragments (obtaining “fused” or
“hybrid” molecule). Our previous research on the antiinflammatory agent topic allowed us to identify
different pyrazolylureas 1 and imidazopyrazoles 2 (Figure 1) able to inhibit the neutrophil movement
towards inflamed tissues (chemotaxis inhibitors) with IC50 values in the pico–micromolar range [3–5].
Pyrazolylureas 1 inhibited only interleukin 8 (IL8)-induced chemotaxis while imidazopyrazoles
2 inhibited only formylmethyl-leucyl-phenylalanine (fMLP)-induced chemotaxis. The molecular
stiffening of previous compounds 1 generates a new class of imidazo-pyrazole derivatives where the
urea group is in part inserted in the cycle and in part on the lateral chain (compounds 3, Figure 1). The
new class of compounds 3 obtained by overlapping 1 and 2 was also considered a successful example
of hybrid derivatives. Indeed, they showed a good dual activity against both IL-8 and fMLP-induced
chemotaxis, with IC50 values in the nanomolar range [6], by inhibiting p38 mitogen-activated protein
kinase (MAPK) phosphorylation, while no inhibition was observed on superoxide anion production
and lysozyme release [7].
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In the same years we developed a large library of phosphodiesterase type 4D inhibitors 
(PDE4DIs). Among them many compounds (particularly GEBR-54 [8] and GEBR-32a [9], Figure 2) 
showed interesting PDE4D3 selective inhibition, and in vitro and in vivo assays evidenced their great 
potential as memory and cognitive performance enhancers (particularly in AD) without causing side-
effects, such as sedation or emesis, in comparison with other PDE4Is [8–10]. On the other hand, 
PDE4Is have been largely studied for their anti-inflammatory effects, particularly in autoimmune 
diseases such as psoriasis [11], asthma and chronic obstructive pulmonary disease (COPD) [12,13]. 
More recently, several evidences suggested PDE4Is also for neurodegenerative inflammatory 
diseases [9,14]. The first series of PDE4Is synthesized by our research group showed a great anti-
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as psoriasis [11], asthma and chronic obstructive pulmonary disease (COPD) [12,13]. More recently,
several evidences suggested PDE4Is also for neurodegenerative inflammatory diseases [9,14]. The
first series of PDE4Is synthesized by our research group showed a great anti-inflammatory activity: in
particular, compound GEBR-4a (Figure 2) and some analogues were able to reduce the superoxide
anion and to increase cAMP intracellular level in a dose dependent manner, activity strictly related to
PDE4 inhibition [15].
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Supported by the interesting results obtained with hybrid derivatives 3, and also having in mind 
the potential role of PDE4Is in inflammation, we designed new hybrid compounds to obtain 
molecules able to act on inflammation through different mechanism. The pyrazole and imidazo-
pyrazole scaffolds present in compounds 1, 2 and 3 were linked, through an acylhydrazone chain, to 
a substituted catechol portion that characterized our previous PDE4Is. The acylhydrazone linker was 
suggested by published analogue PDE4Is [16]. Different alky or aryl substituents were inserted on 
the catechol oxygens in the new compounds 4 and 5, to increase the molecular diversity and to obtain 
more information for structure-activity-relationship (SAR) studies; in many of the new synthesized 
compounds the OCHF2 group has been inserted instead of OCH3, in analogy to the more active 
previous GEBR compounds. Once, also a trifunctionalized phenolic scaffold was used (Figure 3, 
Table 1). In compound 4k a pyrrole was inserted in position 5, to verify if a free NH2 is necessary for 
the activity. For the same reason, the NH in position 1 of the imidazopyrazole 5d was acetylated, thus 
obtaining compound 5k. 
Compounds 4d and 5d, selected on the basis of their similarity with the parental GEBR 
molecules, were preliminary tested to evaluate the chemotaxis inhibition and H2O2 production in 
human neutrophils fMLP stimulated, in order to compare them with compounds 3. Surprisingly, the 
compounds showing very low or absent chemotaxis (data not shown), whereas a potent antioxidant 
activity emerged, as reported in the Results section.  
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oxygen species (ROS) production. Oxidative stress occurs in response to injury or to altered metabolic 
state as a result of an excessive formation of bioactive oxidation products with respect to the capacity 
of the endogenous scavenging mechanism. ROS are important cellular and tissue damage mediators 
and are implicated in many pathological processes such as atherosclerosis [17], diabetes [18], 
neurodegeneration [19], aging [20] and inflammation [17]. 
As reported before, interesting antioxidant activity was already observed for our PDE4 inhibitor 
GEBR-4a and also other rolipram analogues [21]. Therefore, to clarify if the antioxidant activity 
revealed by hybrid compounds 4 and 5, was only due to a cAMP increase or to an independent 
additional mechanism, we planned to evaluate the ROS production inhibition on human platelets, 
instead of neutrophils, as platelets are lacking in PDE4 enzymes but, in addition to their central role 
in the haemostatic process, are involved in the inflammatory process and in the ROS production 
[22,23]. 
To date inflammation, thrombosis and haemostasis are reorganized as processes with 
overlapping steps and connecting pathways. Following injury to blood vessels, such as during 
inflammation, platelets adhere to endothelium with subsequent thrombin formation. Platelet 
response to thrombin include cytoskeleton reorganization, degranulation and secretion of 
proinflammatory cytokines, such as IL-1, tumor growth factor (TGF), platelet derived growth factor 
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Compounds 4d and 5d, s lected on the basis of their similarity with the parental GEBR molecules,
were liminary tested to evaluate the chemotaxis inhibition and H2O2 production in human
neutrophils fMLP stimulated, in order to compare them with compounds 3. Surprisingly, the
compounds showing very low or absent chemotaxis (data not shown), whereas a potent antioxidant
activity emerged, as reported in the Results section.
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Table 1. Decorations on the hybrid structures 4a–k, 5a–k and the benzaldehydes 8a–m used for
their preparation.
Comp. R R1 R2 R3 R4
4a, 8a H O-CH3 O-CHF2 H NH2
4b, 8b O-cyclopentyl O-CH3 H H NH2
4c, 8c H O-CH(CH3)CH2CH3 O-CH3 H NH2
4d, 8d H O-cyclopentyl O-CH3 H NH2
4e, 8e H O-cyclopentyl O-CHF2 H NH2
4f, 8f H O-C6H5 O-CHF2 H NH2
4g, 8g H O-CH2C6H5 O-CHF2 H NH2
4h, 8h H O-CH3 O-CH3 O-CH3 NH2
4i, 8i O-C6H5 O-CH3 H H NH2
4j, 8j O-CH2C6H5 O-CH3 H H NH2
4k, 8d H O-cyclopentyl O-CH3 H 1-pyrrolyl
5a, 8k H O-CH3 O-CH3 H H
5b, 8b O-cyclopentyl O-CH3 H H H
5c, 8c H O-CH(CH3)CH2CH3 O-CH3 H H
5d, 8d H O-cyclopentyl O-CH3 H H
5e, 8e H O-cyclopentyl O-CHF2 H H
5f, 8l H O-cyclohexyl O-CH3 H H
5g, 8m H O-CH2-O H H
5h, 8h H O-CH3 O-CH3 O-CH3 H
5i, 8i O-C6H5 O-CH3 H H H
5j, 8j O-CH2C6H5 O-CH3 H H H
5k, 8d H O-cyclopentyl O-CH3 COCH3
Inflammation and oxidative stress are deeply connected since inflammation can lead to reactive
oxygen species (ROS) production. Oxidative stress occurs in response to injury or to altered metabolic
state as a result of an excessive formation of bioactive oxidation products with respect to the
capacity of the endogenous scavenging mechanism. ROS are important cellular and tissue damage
mediators and are implicated in many pathological processes such as atherosclerosis [17], diabetes [18],
neurodegeneration [19], aging [20] and inflammation [17].
As reported before, interesting antioxidant activity was already observed for our PDE4 inhibitor
GEBR-4a and also other rolipram analogues [21]. Therefore, to clarify if the antioxidant activity
revealed by hybrid compounds 4 and 5, was only due to a cAMP increase or to an independent
additional mechanism, we planned to evaluate the ROS production inhibition on human platelets,
instead of neutrophils, as platelets are lacking in PDE4 enzymes but, in addition to their central role in
the haemostatic process, are involved in the inflammatory process and in the ROS production [22,23].
To date inflammation, thrombosis and haemostasis are reorganized as processes with overlapping
steps and connecting pathways. Following injury to blood vessels, such as during inflammation,
platelets adhere to endothelium with subsequent thrombin formation. Platelet response to thrombin
include cytoskeleton reorganization, degranulation and secretion of proinflammatory cytokines, such as
IL-1, tumor growth factor (TGF), platelet derived growth factor (PDGF); therefore thrombin contribute
to modifying endothelial function participating in the spreading of an inflammatory lesion [22,23].
2. Results and Discussion
2.1. Chemistry
Compounds 4a–k and 5a–k (Scheme 1, Table 1) were obtained by refluxing the suitable
benzaldehydes 8a–m solved in a mixture of absolute ethanol/methanol (7:3) in the presence of
the pyrazolylcarbohydrazides 7, 10 or the imidazopyrazolyl carbohydrazide 12, respectively.
Molecules 2020, 25, 899 5 of 18
Molecules 2020, 25, x FOR PEER REVIEW 5 of 17 
Intermediate 7 was prepared by reacting an excess of hydrazine monohydrate with the ethyl 5-
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phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-7-carboxylate (11) [4] by dehydration in concentrated 
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prepare derivatives 4 and 5, the suitable benzaldehydes 8h and 8m (Table 1) were purchased, while 
the others were prepared following well known procedures. In details, the 3-phenoxy-substituted 
benzaldehydes 8f and 8i were obtained by adding diphenyliodonium chloride to 3-hydroxy-4-
difluoromethoxy-benzaldehyde [34] (for 8f) or 2-hydroxy-3-methoxy-benzaldehyde (for 8i) 
previously converted into the salt forms with NaOH aqueous solution (Crowder’s method [35]). The 
others intermediates were prepared by alkylation with the appropriate alkyl chloride in the presence 
of K2CO3 [36] starting from the corresponding phenolic benzaldehydes: in particular from 3-hydroxy-
4-difluoromethoxy benzaldehyde (to obtain 8a, e, f, g), from isovanillin (to prepare 8c, d, l), from 
vanillin (for 8k), and from 2-hydroxy-3-methoxybenzaldehyde (compounds 8b, 8i, 8j). Finally, 
compound 5k was obtained from 5d by treatment with acetic anhydride in the presence of sodium 
acetate. 
 
Scheme 1. Synthesis of compounds 4 and 5. Reagents and conditions: (i) hydrazine monohydrate, 120–
130 °C, 4 h; (ii) abs. EtOH/MeOH (7:3), reflux, 18 h; (iii) 2,5-dimethoxytetrahydrofuran, acetic acid, 
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Since in the presence of high intracellular ROS platelets demonstrate increased activation by 
agonists and ROS elevation leads to platelet aggregation that can in turn worsen the inflammation 
status, preliminary we have tested the aggregation inhibiting effect of compounds as detailed in the 
Experimental section. Results of aggregation inhibition and ROS production inhibition are reported 
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4a, 4f and 4g the most active with IC50 values around 10 µM. Interestingly, the same 4a, 4f and 4g 
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Scheme 1. Synthesis of compounds 4 and 5. Reagents and conditions: (i) hydrazine monohydrate,
120–130 ◦C, 4 h; (ii) abs. EtOH/MeOH (7:3), reflux, 18 h; (iii) 2,5-dimethoxytetrahydrofuran, acetic acid,
reflux, 4 h; (iv) conc. H2SO4, 0 ◦C, 15 min; (v) acetic anhydride, CH3COONa, 40–50 ◦C, 4 h.
Although formation of E/Z mixtures is possible, only one of the two isomers has been always
obtained as confirmed by 1H- and 13C-NMR spectra. Since aldehyde hydrazones generally adopt
C=N E-geometry [24] and E-geometry was always assigned to the predominant or single isomer
obtained [25–30], for the prepared acyl hydrazones, the E configuration was a priori hypothesized.
Once acquired NMR spectra, the E-geometry was definitively assigned on the basis of the CONH
group proton atom chemical shift (δ 11.23 ppm), in accordance to the literature data. In this regard,
to a series of hydrazone derivatives, having signals of the NH group <12 ppm as in our case, the E
configuration was assigned by NOESY experiments and DFT calculations [31]. Furthermore, it was
also reported that NH chemical shift for Z isomers is instead moved to much higher delta values (δ >
15.5 ppm) [32]. 1H-NMR spectra images are reported in the Supporting Information.
Intermediate 7 was prepared by reacting an excess of hydrazine monohydrate with the ethyl
5-amino-1-(2-hydroxy-2-phenylethyl)-1H-pyrazole-4-carboxylate 6 [33] (Scheme 1). We obtained the
5-pyrrolyl analogue 9 by refluxing the pyrazolyl ethyl carboxylate 6 in 2,5-dimethoxy-tetrahydrofuran
in the presence of acetic acid. Moreover, starting from the same compound 6 we prepared
ethyl 2-phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-7-carboxylate (11) [4] by dehydration in
concentrated sulfuric acid. The carbohydrazides 10 and 12 were obtained by the same procedure
used for 7. To prepare derivatives 4 and 5, the suitable benzaldehydes 8h and 8m (Table 1) were
purchased, while the others were prepared following well known procedures. In details, the
3-phenoxy-substituted benzaldehydes 8f and 8i were obtained by adding diphenyliodonium chloride
to 3-hydroxy-4-difluoromethoxy-benzaldehyde [34] (for 8f) or 2-hydroxy-3-methoxy-benzaldehyde
(for 8i) previously converted into the salt forms with NaOH aqueous solution (Crowder’s method [35]).
The others intermediates were prepared by alkylation with the appropriate alkyl chloride in the
presence of K2CO3 [36] starting from the corresponding phenolic benzaldehydes: in particular from
3-hydroxy-4-difluoromethoxy benzaldehyde (to obtain 8a, e, f, g), from isovanillin (to prepare 8c,
d, l), from vanillin (for 8k), and from 2-hydroxy-3-methoxybenzaldehyde (compounds 8b, 8i, 8j).
Finally, compound 5k was obtained from 5d by treatment with acetic anhydride in the presence of
sodium acetate.
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2.2. ROS Production and Aggregation Inhibition Evaluated in Human Platelets in the Presence of Compounds
4a–k and 5a–k
Since in the presence of high intracellular ROS platelets demonstrate increased activation by
agonists and ROS elevation leads to platelet aggregation that can in turn worsen the inflammation
status, preliminary we have tested the aggregation inhibiting effect of compounds as detailed in the
Experimental section. Results of aggregation inhibition and ROS production inhibition are reported in
Table 2. Most of the tested compounds were able to inhibit aggregation and ROS production, being 4a,
4f and 4g the most active with IC50 values around 10 µM. Interestingly, the same 4a, 4f and 4g were
the most active also as platelet aggregation inhibitors.
Table 2. Inhibiting effect of compounds 4a–k and 5a–j on aggregation and reactive oxygen species
(ROS) production expressed as IC50 (µM) values. Reported data are the mean +/- SD obtained in at
least six different experiments each performed in duplicate.
Compd. Aggregation Inhibition IC50 (µM) ROS production Inhibition IC50 (µM)
4a 7.6 ± 0.5 10.1 ± 2.1
4b 64 ± 2.5 20.5 ± 2.5
4c 57.1 ± 1.6 16.7 ± 1.1
4d 29.8 ± 3.7 38.3 ± 2.8
4e 29.4 ± 4.4 32.8 ± 2.8
4f 9.8 ± 1.7 8.6 ± 2.2
4g 11.0 ± 1.2 9.5 ± 2.6
4h >200 >200
4i >200 >200
4j >200 >200
4k 86.1 ± 7.8 92.7 ± 5.8
5a 31.5 ± 5.2 37.2 ± 2.5
5b 59.1 ± 5.5 66.7 ± 5.7
5c 70.9 ± 4.0 71.4 ± 6.0
5d 71.0 ± 6.8 70.6 ± 7.4
5e 70.5 ± 8.0 78.8 ± 5.6
5f 61.6 ± 6.5 59.9 ± 5.7
5g 67.0 ± 6.6 77.9 ± 7.1
5h >200 >200
5i >200 >200
5j >200 >200
5k >200 >200
2.3. Structure-Activity Relationships
SAR analysis clearly indicated that the OCHF2 substituent at position 4 is a pivotal structural
characteristic, while the substituent in position 3 seems not to be determinant for potency. Another clear
evidence is that compounds bearing the pyrazole nucleus are more active than the imidazo-pyrazole
ones. This is particularly evident by comparing 4b, 4c, 4d and 4e to the corresponding imidazopyrazole
derivatives 5b, 5c, 5d and 5e, the potency of the first group being approximately from two to four
times higher than the second ones.
In addition, we can point out that two substituents in the positions 3 and 4 of the aromatic ring are
positive for biological activity, differently than the trisubstitution: in fact, both analogues 4h and 5h are
inactive. A bulky substituent such as a cyclopentyl in position 2 instead of 3 is well tolerated: indeed,
we observed a slight increase of activity in the pyrazole series (compare 4b with the regioisomer 4d)
or no change in the imidazopyrazole series (compare 5b with 5d); whereas, aromatic substituents
such benzyloxy or phenoxy in position 2 are detrimental for the activity; in fact, 4i, 4j, 5i and 5j are
completely inactive. A slight reduction of activity is also evident when the meta and para substituents
are closed in a ring (see compound 5g).
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Moreover, it is noteworthy that the presence of a free amino group at position 5 of the pyrazole
ring is fundamental to block ROS production, as the 5-pyrrolyl compound 4k showed lower activity
compared to the 5-NH2-substituted analogue 4d (IC50 = 90 µM versus 40 µM). A similar result was
obtained by acetylating the NH group in position 1 of the imidazopyrazole ring, being the acetyl
derivative 5k completely inactive, while the corresponding 5d showed an IC50 value of 70.6 µM. This
observation suggests that, even if the imidazopyrazoles are in general less active than the pyrazole
ones, the effect on ROS production could be due to the same mechanism, which probably requires an
H-bond donor group and a good degree of molecule flexibility.
Finally, we also tested in the same assay the intermediates 7 and 12 in order to confirm that the
ROS production inhibition of compounds 4 and 5 is due to the molecule hybridization and not to
the pyrazole or imidazopyrazole scaffold alone. As we hypothesized, both 7 and 12 were completely
inactive towards ROS production in platelets, as well as in neutrophils (data not shown). For the same
reason we tested on platelets also some compounds among the previous series 3 that resulted inactive
as well (data not shown).
2.4. Flow Cytometric Evaluation of ROS Production on Human Neutrophils in the Presence of Compounds 4d
and 5d
As reported in the introduction, to verify if the pharmacological activities already evidenced
in previous compounds was maintained, preliminary tests were performed on some of the new
hybrid compounds (in particular 4d and 5d, bearing the catechol structure typical of previously
synthesized PDE4DIs). Firstly, the ability of 4d and 5d in inhibiting neutrophil chemotaxis were
evaluated in order to compare the results with compound GEBR-4a. Unexpected negative results (data
not shown) suggested that newly synthesized compounds should have a different target. Consequently,
the ability to inhibit ROS production was also evaluated on neutrophils fMLP activated using flow
cytometric analysis, according to literature method [37]. Interestingly compounds 4d and 5d at 10 µM
concentration were able to inhibit ROS production with an inhibition percentage of 68% and 63%
respectively, using the 2′,7′-dichlorofluorescein diacetate method (DCFH-DA), a fluorogenic dye that
measures hydroxyl, peroxyl and other reactive oxygen species.
In Figure 4 we report the intracellular ROS level inhibition (4A) and the corresponding
dose-dependent effect (4B) of 4d alone, since results were very similar for 5d. In the same test
also the intermediates 7 and 12 were evaluated and resulted inactive (data not shown). In addition, at
the same time, using propidium iodide (PI) method [38], we assessed cell vitality and no cytotoxic
action of both compounds at 10 µM concentration. Propidium iodide is able to penetrate only
the compromised membrane of plasma cells and therefore causes red fluorescence by binding to
double-stranded DNA. On the contrary it don’t cross intact plasma cell membrane, therefore no red
fluorescence is present in vital cells, as evidenced in Figure 4C. Cell viability was over than 95%.
2.5. Enzymatic Assays on PDE4
Compounds 4d and 5d were tested on enzymatic assay to verify the ability to inhibit PDE4D3 and
PDE4B2, the isoforms most investigated in our previous studies (see experimental section). Results
indicated that hybrid compounds 4d and 5d are able to strongly inhibit both isoforms and no differences
were evidenced between pyrazole or imidazopyrazole scaffold. Indeed, 4d showed IC50 values of
1.05 µM on PDE4D3 and 0.55 µM on PDE4B2; similarly, 5d showed IC50 of 1.22 µM on PDE4D3 and
0.55 µM on PDE4B2. Preliminary evaluation of compound 4d (at 10 µM concentration) on PDE1, PDE2,
PDE3, PDE5 and PDE7 was already performed and no inhibition was observed (data not shown).
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compound 4d in formyl-methyl-leucyl-phenylalanine (fMLP)-activated neutrophils. (A): reactive
oxygen species (ROS) intracellular level reduction (B): dose-dependent effect of compound on ROS
reduction (C): cell vitality determined by PI method. Data are expressed as mean ± SD and are
representative of four separate experiments.
3. Experimental
3.1. General Information
All chemicals were purchased from Chiminord and Aldrich Chemical (Milan, Italy). Solvents were
reagent grade. Unless otherwise stated, all commercial reagents were used without further purification.
Aluminium- backed silica gel plates (DC-Alufolien Kieselgel 60 F254, Merck, Darmstadt, Germany),
were used in thin-layer chromatography (TLC) for routine monitoring the course of reactions. Detection
of spots was made by UV light. Merck silica gel, 230–400 mesh, was used for chromatography. Melting
points are not “corrected” and were measured with an M-560 instrument (Buchi instruments, Flawil,
Switzerland). IR spectra were recorded with a 398 spectrophotometer (Perkin-Elmer, Milan, Italy). 1H
NMR spectra were recorded on a Gemini 200 (200 MHz, Varian Gemini, Palo Alto, CA, USA) and a
DPX-300 (300 MHz) instrument (Bruker, Billerica, MA, USA); chemical shifts are reported as δ (ppm)
relative to tetramethylsilane (TMS) as internal standard; signals were characterized as s (singlet), d
(doublet), t (triplet), q (quartet), m (multiplet), br s (broad signal), n t (near triplet); J in Hz. Elemental
analyses were determined with an elemental analyzer EA 1110 (Fison-Instruments, Milan, Italy) and
the purity of all synthesized compounds was >95% (see Supplementary Materials). Flow cytometric
assays were performed by flow cytometry (FC500, Beckman Coulter, Hialeah, FL, USA).
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3.2. Synthesis
3.2.1. General Procedure for 5-amino-1-(2-hydroxy-2-phenylethyl)-1H-pyrazole-4-carbohydrazide (7)
and 2-phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-7-carbohydrazide (12)
A mixture of 5-amino-1-(2-hydroxy-2-phenylethyl)-1H-pyrazole-4-carboxylic acid ethyl ester (6,
0.81 g, 3.1 mmol) or 2-phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-7-carboxylic acid ethyl ester
(11, 0.8 g, 3.1 mmol) and hydrazine monohydrate (5 mL, 100 mmol) was stirred at 120 ◦C for 8 h.
After cooling to room temperature, water (10 mL) was added and the obtained solids were purified
by Florisil column cromatography using a diethyl ether/methanol mixture (9:1) as the eluent. The
obtained solids were then recrystallized by ethanol/methanol (2:1).
5-Amino-1-(2-hydroxy-2-phenylethyl)-1H-pyrazole-4-carbohydrazide (7). White solid. Yield 48%. Mp:
183–184 ◦C. IR (KBr) cm−1: 3513, 3389 (NH2), 3316 (OH), 1603 (C=O). 1H-NMR (CDCl3): δ 3.90–4.08
(m, 2H, CH2N), 4.21 (br s, 2H, NH2 disappears with D2O), 4.86–5.03 (m, 1H, CHOH), 5.72 (d, J = 4.6,
1H, OH, disappears with D2O), 6.04 (br s, 2H, NH2, disappears with D2O), 7.21–7.47 (m, 5H, Ar), 7.66
(s, 1H, H3 pyraz.), 8.96 (br s, 1H, CONH, disappears with D2O). Analysis (%) calcd. for C12H15N5O2.
2-Phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-7-carbohydrazide (12). White solid. Yield 66%. Mp
250–252 ◦C. IR (KBr) cm−1: 3296 (NH2), 1627 (C=O). 1H-NMR (DMSO-d6) δ: 3.77 (t, J = 8.0, 1H, H3),
4.26 (s, 2H, NH2, disappears with D2O), 4.57 (t, J = 8.0, 1H, H2), 5.42 (dt, J = 4.0, J = 8.0, 1H, H3),
7.04 (br s, 1H, NH, disappears with D2O), 7.26–7.52 (m, 5H, Ar), 7.67 (s, 1H, H6), 8.80 (s, 1H, CONH,
disappears with D2O). Analysis (%) calcd. for C12H13N5O.
3.2.2. Preparation of Ethyl 1-(2-hydroxy-2-phenylethyl)-5-(1H-pyrrol-1-yl)-1H-pyrazole-
4-carboxylate (9)
To a solution of 5-amino-1-(2-hydroxy-2-phenylethyl)-1H-pyrazole-4-carboxylic acid ethyl ester
(6) [33] (0.27 g, 1 mmol) in glacial acetic acid (3 mL), 2,5-dimethoxytetrahydrofuran (0.15 g, 1.1 mmol)
was added and the mixture was stirred at reflux temperature for 2 h. After cooling to room temperature,
the mixture was diluted with water (10 mL) and extracted with ethyl acetate (3 × 10 mL). The organic
phase was washed with sodium hydrogen carbonate saturated solution (1 × 10 mL), water (1 × 10 mL),
dried (MgSO4) and concentrated under reduced pressure to give an oil that was purified by silicagel
column chromatography using as the eluent firstly dichloromethane, then diethylether. The product
was obtained as a white solid. Yield: 55%. Mp: 103–104 ◦C. IR (KBr) cm−1: 3318 (OH), 1687 (C=O).
1H-NMR (CDCl3): δ 1.22 (t, J = 6.4, 3H, CH3), 2.90 (br s, 1H, OH disappears with D2O), 4.03–4.29 (m,
4H, CH2O + CH2N), 5.12–5.22 (m, 1H, CHOH), 6.35 (s, 2H, H2 pyrr.), 6.58 (s, 2H, H3 pyrr.), 7.17–7.52
(m, 5H, Ar), 8.09 (s, 1H, H3 pyraz.). Analysis (%) calcd. for C18H19N3O3.
3.2.3. Preparation of 1-(2-hydroxy-2-phenylethyl)-5-(1H-pyrrol-1-yl)-1H-pyrazole-
4-carbohydrazide (10)
Ethyl 1-(2-hydroxy-2-phenylethyl)-5-(1H-pyrrol-1-yl)-1H-pyrazole-4-carboxylate (9, 0.50 g,
1.53 mmol) was solved in hydrazine monohydrate (5 mL) and the mixture was stirred at reflux
for 5 h. After cooling to room temperature, the mixture was diluted with water (10 mL) and extracted
with ethyl acetate (3 × 10 mL). The organic phase was washed with brine (2 × 10 mL), dried (MgSO4)
and concentrated under reduced pressure to give an oil that was purified by Silica gel column
chromatography using dichloromethane, as the eluent. The oil residue was crystallized by ethanol
obtaining the final product as a white solid. Yield: 61%. Mp: 145–146 ◦C. 1H-NMR (CDCl3): δ 3.88 (d,
J = 6.4, 2H, CH2N), 4.29 (br s, 2H, NH2 disappears with D2O), 4.88-4.99 (m, 1H, CHOH), 5.74 (d, J = 4.4,
1H, OH disappears with D2O), 6.24 (s, 2H, H2 pyrr.), 6.78 (s, 2H, H3 pyrr.), 7.04–7.41 (m, 5H, Ar), 8.00
(s, 1H, H3 pyraz.), 9.07 (br s, 1H, CONH disappears with D2O). Analysis calcd. for C16H17N5O2.
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3.2.4. General Procedure for (E)-5-amino-1-(2-hydroxy-2-phenylethyl)-N′-benzylidene-1H-pyrazole-
4-carbohydrazides 4a–k and N′-benzylidene-2-phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-
7-carbohydrazides 5a–j
A solution of a suitable benzaldehyde 8 (2 mmol) in a mixture of ethanol/methanol (7:3,
5 mL) was added dropwise to 5-amino-1-(2-hydroxy-2-phenylethyl)-1H-pyrazole-4-carbohydrazide
(7) or 1-(2-hydroxy-2-phenylethyl)-5-(1H-pyrrol-1-yl)-1H-pyrazole-4-carbohydrazide (10) or
2-phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-7-carbohydrazide (12) (2 mmol) solved in the same
mixture solvent (15 mL). The reaction mixture was stirred at 100 ◦C for 18 h, cooled to room temperature
and poured into ice water (10 mL). The white solids obtained were simply dried, if pure at TLC check
(Silica gel, diethyl ether/methanol (8:2)), or recrystallized by absolute ethanol or ethyl acetate.
(E)-5-Amino-N′-(4-(difluoromethoxy)-3-methoxybenzylidene)-1-(2-hydroxy-2-phenylethyl)-1H-pyrazole-
4-carbohydrazide (4a). Yield 63%. White solid. Mp: 119–121 ◦C. 1H-NMR (DMSO-d6): δ 3.91 (s, 3H,
OCH3), 3.94–4.15 (m, 2H, CH2N), 4.94–5.11 (m, 1H, CHOH), 5.72 (s, 1H, OH, disappears with D2O),
6.77 (br s, 2H, NH2, disappears with D2O), 7.10–7.70 (m, 9H, 5Ar + H2 Ar + H5 Ar + H6 Ar + OCHF2),
7.82–8.20 (m, 2H, CH=N + H3 pyraz.), 11.20 (s, 1H, CONH, disappears with D2O). Anal calcd. for
C21H21F2N5O4.
(E)-5-Amino-N′-(2-(cyclopentyloxy)-3-methoxybenzylidene)-1-(2-hydroxy-2-phenylethyl)-1H-pyrazole-
4-carbohydrazide (4b). Yield 46%. White solid. Mp: 180–181 ◦C. IR (KBr) cm−1: 3427 (OH), 3321,
3323, 3139 (NH2 + NH), 1634 (C=O), 1572 (C=N). 1H-NMR (DMSO-d6): δ 1.40–2.00 (m, 8H, 4CH2
cyclopent.), 3.78 (s, 3H, OCH3), 3.90–4.80 (m, 2H, CH2N), 4.80–4.90 (m, 1H, OCH cyclopent), 4.95–5.05
(m, 1H, CHOH), 5.65–5.75 (m, 1H, OH, disappears with D2O), 6.20–6.50 (br s, 2H, NH2, disappears
with D2O), 6.68 and 7.12 (qAB, J =10.0, 2H, Ar), 7.20–7.50 (m, 6H, Ar), 7.80–8.20 (m, 2H, CH=N + H3
pyraz.), 11.03 (s, 1H, CONH, disappears with D2O). Anal calcd. for C25H29N5O4.
(E)-5-Amino-N′-(3-(sec-butoxy)-4-methoxybenzylidene)-1-(2-hydroxy-2-phenylethyl)-1H-pyrazole-
4-carbohydrazide (4c). Yield 64%. White solid. Mp: 190–193 ◦C. IR (KBr) cm−1: 3427 (OH),
3325, 3234, 3196 (NH2 + NH), 1644 (C=O), 1614 (C=N). 1H-NMR (DMSO-d6): δ 0.91–0.94 (m, 3H,
CH3CH2), 1.18–1.35 (m, 3H, CH3CH), 1.40–1.80 (m, 2H, CH3CH2), 3.30–3.40 (m, 1H, CHCH3), 3.79 (s,
3H, OCH3), 3.90–4.20 (m, 2H, CH2N), 4.95–5.05 (m, 1H, CHOH), 5.60–5.80 (m, 1H, OH, disappears
with D2O), 6.15–6.55 (m, 2H, NH2, disappears with D2O), 6.90–7.50 (m, 8H, Ar), 7.70–8.30 (m, 2H,
CH=N +H3 pyraz.), 11.01 (s, 1H, CONH, disappears with D2O). Anal calcd. for C24H29N5O4.
(E)-5-Amino-N′-(3-(cyclopentyloxy)-4-methoxybenzylidene)-1-(2-hydroxy-2-phenylethyl)-1H-pyrazole-
4-carbohydrazide (4d). Yield 78%. White solid. Mp: 193–195 ◦C. IR (KBr) cm−1: 3324, 3219 (NH), 2970
(OH), 1615 (C=N), 1642 (CONH). 1H-NMR (CDCl3): δ 1.48–2.10 (m, 8H, cyclopent.), 3.89 (s, 3H,
OCH3), 4.02–4.33 (m, 2H, CH2N), 4.78–4.99 (m, 1H, OCH cyclopent.), 5.11–5.32 (m, 1H, CHOH), 5.82
(br s, 2H, NH2 disappears with D2O), 6.80–7.01 (m, 1H, H5 Ar), 7.04–7.22 (m, 1H, H6 Ar), 7.22–7.61 (m,
7 H, 6H Ar + H2 Ar), 7.75–8.38 (m, 2H, CH=N + H3 pyraz.), 9.00 (br s, 1H, CONH, disappears with
D2O). Anal calcd. for C25H29N5O4.
(E)-5-Amino-N′-(3-(cyclopentyloxy)-4-(difluoromethoxy)benzylidene)-1-(2-hydroxy-2-phenylethyl)-
1H-pyrazole-4-carbohydrazide (4e). Yield 96%. White solid. Mp: 178–180 ◦C. IR (KBr) cm−1:
3450–3200 (NH + OH), 1635 (CONH). 1H-NMR (DMSO-d6): δ 1.51–2.04 (m, 8H, 4CH2 cyclopent.),
3.30–3.40 (m, 2H, CH2N), 3.90–4.21 (m, 1H, CHOH), 4.84–5.10 (m, 1H, OCH cyclopent.), 5.75 (s, 1H,
OH, disappears with D2O), 6.42 (br s, 2H, NH2, disappears with D2O), 7.06–7.60 (m, 9H, 5Ar + H2 Ar +
H5 Ar + H6 Ar + OCHF2), 7.83–8.35 (m, 2H, CH=N + H3 pyraz.), 11.20 (s, 1H, CONH, disappears with
D2O). Anal calcd. for C25H27F2N5O4.
(E)-5-Amino-N′-(4-(difluoromethoxy)-3-phenoxybenzylidene)-1-(2-hydroxy-2-phenylethyl)-1H-pyrazole-
4-carbohydrazide (4f). Yield 38%. White solid. Mp: 184–186 ◦C. 1H-NMR (CDCl3): δ 3.92–4.26 (m, 2H,
CH2N), 5.08–5.23 (m, 1H, H3 pyraz.), 6.60–6.78 (br s, 2H, NH2, disappears with D2O), 7.17–7.38 (m,
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14H, 10Ar + H2 Ar + H5 Ar + H6 Ar + OCHF2), 7.97–8.38 (m, 2H, CH=N + H3 pyraz.), 9.18–9.40 (s, 1H,
CONH, disappears with D2O). Anal calcd. for C26H23F2 N5O4.
(E)-5-Amino-N′-(3-(benzyloxy)-4-(difluoromethoxy)benzylidene)-1-(2-hydroxy-2-phenylethyl)-1H-pyrazole-
4-carbohydrazide (4g). Yield 61%. White solid. Mp: 144–146 ◦C. 1H-NMR (DMSO-d6): δ 3.95–4.20 (m,
2H, CH2N), 4.92–5.10 (m, 1H, CHOH), 5.26 (s, 2H, CH2Bz), 5.75 (s, 1H, OH, disappears with D2O), 6.40
(br s, 2H, NH2, disappears with D2O), 7.16–7.70 (m, 14H, 10Ar + H2 Ar + H5 Ar + H6 Ar + OCHF2),
7.83–8.35 (m, 2H, CH=N + H3 pyraz.), 11.25 (s, 1H, CONH, disappears with D2O). Anal calcd. for
C27H25F2N5O4.
(E)-5-Amino-1-(2-hydroxy-2-phenylethyl)-N′-(3,4,5-trimethoxybenzylidene)-1H-pyrazole-4-carbohydrazide
(4h). Yield 34%. White solid. Mp: 176–178 ◦C. IR (KBr) cm−1: 3490 (OH), 3435, 3391, 3341, 3239 (NH2
+NH), 1640 (CO), 1561 (C=N). 1H-NMR (DMSO-d6): δ 3.36 (s, 3H, OCH3), 3.71 (s, 3H, OCH3), 3.83 (s,
3H, OCH3), 4.40–4.10 (m, 2H, CH2N), 4.95–5.05 (m, 1H, CHOH), 5.70–5.80 (m, 1H, OH, disappears with
D2O), 6.25–6.55 (br s, 2H, NH2, disappears with D2O), 6.98 (s, 2H, Ar), 7.25–7.50 (m, 5H, Ar), 7.80–8.20
(m, 2H, CH=N + H3 pyraz.), 11.18 (s, 1H, CONH, disappears with D2O). Anal calcd. for C22H24N4O5.
(E)-5-Amino-1-(2-hydroxy-2-phenylethyl)-N′-(3-methoxy-2-phenoxybenzylidene)-1H-pyrazole-4-carbohydrazide
(4i). Yield 66%. White solid. Mp: 207–209 ◦C. IR (KBr) cm−1: 3395 (OH), 3324, 3287, 3206, 3239 (NH2
+NH), 1646 (CO), 1551 (C=N). 1H-NMR (DMSO-d6): δ 3.69 (s, 3H, OCH3), 3.85–4.15 (m, 2H, CH2N),
4.90–5.05 (m, 1H, CHOH), 5.69 (d, J = 2.0, 1H, OH, disappears with D2O), 6.20–6.50 (br s, 2H, NH2,
disappears with D2O), 6.78 (d, J = 4.0, 1H, Ar), 7.00 (t, J = 4.0, 1H, Ar), 7.15–7.45 (m, 10H, Ar), 7.55 (d,
J = 4.0, 1H, Ar), 7.60–8.40 (2 m, 2H, CH=N + H3 pyraz.), 11.20 (s, 1H, CONH, disappears with D2O).
Anal calcd. for C26H25N5O4.
(E)-5-Amino-N′-(2-(benzyloxy)-3-methoxybenzylidene)-1-(2-hydroxy-2-phenylethyl)-1H-pyrazole-
4-carbohydrazide (4j). Yield 71%. White solid. Mp: 198–200 ◦C. IR (KBr) cm−1: 3415 (OH),
3352, 3151, 3034 (NH2 +NH), 1627 (CO), 1564 (C=N). 1H-NMR (DMSO-d6): δ 3.87 (s, 3H, OCH3),
3.90–4.20 (m, 2H, CH2N), 4.85–5.10 (m, 1H, CHOH), 4.99 (s, 2H, CH2Bz), 5.71 (d, J = 2.0, 1H, OH,
disappears with D2O), 6.20–6.60 (br s, 2H, NH2, disappears with D2O), 7.00–7.55 (m, 13H, Ar),
7.80–8.10 (br s, 1H, H3 pyraz.), 8.35–8.55 (br s, 1H, CH=N), 11.19 (s, 1H, CONH, disappears with D2O).
Anal calcd. for C27H27N5O4.
(E)-5-Amino-N′-(3-(cyclopentyloxy)-4-methoxybenzylidene)-1-(2-hydroxy-2-phenylethyl)-1H-pyrazole-
4-carbohydrazide (4k). Yield 80%. White solid. Mp: 206–207 ◦C. IR (KBr) cm−1: 3364, 3309 (NH), 2951
(OH), 1598 (C=N), 1656 (CONH). 1H-NMR (DMSO-d6): δ 1.45–2.15 (m, 8H, cyclopent.), 3.88 (s, 3H,
OCH3), 3.97–4.19 (m, 2H, CH2N), 4.75–4.97 (m, 1H, OCH cyclopent.), 5.17–5.33 (m, 1H, CHOH), 6.57 (s,
2H, H2 pyrr.), 6.73 (s, 2H, H3 pyrr.), 6.78–7.18 (m, 2H, H5 + H6 Ar), 7.22–7.61 (m, 7H, 5Ar + H3 pyraz. +
H2 Ar), 8.38 (s, 1H, CH=N), 9.85 (br s, 1H, CONH, disappears with D2O). Anal calcd. for C29H31N5O4.
(E)-N′-(3,4-Dimethoxybenzylidene)-2-phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-7-carbohydrazide (5a).
Yield 70%. White solid. Mp: 206–207 ◦C. IR (KBr) cm−1: 3432–3213 (NH), 1700–1600 (CONH + C=N).
1H-NMR (DMSO-d6): δ 3.70–3.92 (m, 7H, 2 OCH3 + H3), 4.63 (t, J = 8.0, 1H, H2), 5.48 (n t., 1H, H3),
7.02 (d, J = 7.8, 1H, H5 Ar), 7.09 (dd, J = 7.8, J = 1.6, 1H, H6 Ar), 7.24–7.53 (m, 7H, 5 Ar + H2 Ar + H6),
7.60–8.40 (m, 2H, CH=N + NH, 1H disappears with D2O), 11.10 (s, 1H, CONH, disappears with D2O).
Anal calcd. for C21H21N5O3.
(E)-N′-(2-(Cyclopentyloxy)-3-methoxybenzylidene)-2-phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-
7-carbohydrazide (5b). Yield 78%. White solid. Mp: 150–151 ◦C. IR (KBr) cm−1: 3392–3234 (NH), 1644
(CONH), 1594 (C=N). 1H-NMR (DMSO-d6): δ 1.47–2.20 (m, 8H, cyclopent.), 3.72–3.95 (m, 4H, OCH3 +
H3), 4.62 (n t, 1H, H2), 4.75–4.92 (m, 1H, OCH), 5.48 (n t, 1H, H3), 7.00 (d, J = 10.0, 1H, H5 Ar), 7.18 (dd,
J = 10.0, J =1.8, 1H, H6 Ar), 7.23–7.52 (m, 7H, 5H Ar + H2 Ar + H6), 7.99 (br s, 2H, NH + CH=N, 1H
disappears with D2O), 11.07 (s, 1H, CONH, disappears with D2O). Anal calcd. for C25H27N5O3.
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(E)-N′-(3-(sec-Butoxy)-4-methoxybenzylidene)-2-phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-
7-carbohydrazide (5c). Yield 62%. White solid. Mp: 130–131◦C. IR (KBr) cm−1: 3373 (NH),
1631 (CONH), 1594 (C=N). 1H-NMR (DMSO-d6): δ 0.95 (m, 3H, CH3CH2), 1.25 (d, J = 5.6, 3H, CH3CH),
1.45–1.80 (m, 2H, CH2CH3), 3.60–3.95 (m, 4H, OCH3 + CHCH3), 4.20–4.40 (m, 1H, H3), 4.60 (t, J = 8.0,
1H, H2), 5.40 (t, J = 8.0, 1H, H3), 6.90–7.50 (m, 8H, Ar), 7.95 (br s, 2H, H6 + NH, 1H disappears with
D2O), 11.10 (s, 1H, CONH disappears with D2O). Anal calcd. for C24H27N5O3.
(E)-N′-(3-(cyclopentyloxy)-4-methoxybenzylidene)-2-phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-
7-carbohydrazide (5d). Yield 93%. White solid. Mp: 120–124 ◦C. IR (KBr) cm−1: 3415, 3324 (NH), 1581
(C=N), 1633 (CONH). 1H-NMR (CDCl3): δ 1.47–2.20 (m, 8H, 4CH2 cyclopent.), 3.90 (s, 3H, OCH3),
4.07 (n t, 1H, H3), 4.62 (n t, 1H, H2), 4.79–4.95 (m, 1H, OCH cyclopent.), 5.50 (n t, 1H, H3), 6.83 (d, J =
8.2, 1H, H5 Ar), 7.09 (dd, J = 8.2, J = 1.6, 1H, H6 Ar), 7.29 (d, J = 1.6, 1H, H2 Ar), 7.32–7.52 (m, 5H Ar),
7.82 (s, 1H, H6 pyraz.), 8.25 (br s, 1H, NH disappears with D2O), 9.18 (s, 1H, CH=N), 9.85 (br s, 1H,
CONH disappears with D2O). Anal calcd. for C25H27N5O3.
(E)-N′-(3-(cyclopentyloxy)-4-(difluoromethoxy)benzylidene)-2-phenyl-2,3-dihydro-1H-imidazo[1,2-b]-pyrazole-
7-carbohydrazide (5e). Yield 62%. Red solid. Mp: 104–105 ◦C. IR (KBr) cm−1: 3228, 2961 (NH), 1642
(CONH), 1599 (C=N). 1H-NMR (DMSO-d6): δ 1.52–2.00 (m, 8H, 4CH2 cyclopent.), 3.82 (n t, 1H, H3),
4.64 (n t, 1H, H2), 4.87–4.99 (m, 1H, OCH cyclopent.), 5.48 (n t, 1H, H3), 7.07 (t, 1H, J = 70.0, OCHF2),
7.17–7.54 (m, 10H, 8H Ar + H6 + NH, 1 H disappears with D2O), 7.99 (br s, 1H, CH=N), 11.20 (br s, 1H,
CONH, disappears with D2O). Anal calcd. for C25H25F2N5O3.
(E)-N′-(3-(Cyclohexyloxy)-4-(methoxy)benzylidene)-2-phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-
7-carbohydrazide (5f). Yield 65%. White solid. Mp: 119–120 ◦C. IR (KBr) cm−1: 3584 (NH), 1633
(CONH), 1581 (C=N). 1H-NMR (DMSO-d6): δ 1.20–2.20 (m, 10H, 5CH2 cyclohex.), 3.80–4.10 (m, 4H,
OCH3 + OCH), 4.25 (n t, 1H, H3), 4.52 (n t, 1H, H2), 5.39 (n t, 1H, H3), 6.60–7.60 (m, 8H, Ar), 7.90 (br s,
1H, CH=N), 8.20 (s, 1H, H6), 10.15 (s, 1H, CONH, disappears with D2O). Anal calcd. for C26H29N5O3.
(E)-N′-(benzo[d][1,3]dioxol-5-ylmethylene)-2-phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-7-carbohydrazide
(5g). Yield 93%. White solid. Mp: 230–233 ◦C. IR (KBr) cm−1: 3400, 3227 (NH), 1638 (CONH), 1608
(C=N). 1H-NMR (DMSO-d6): δ 3.82 (n t, 1H, H3), 4.62 (n t, 1H, H2), 5.43 (n t, 1H, H2), 4.96 (br s, 1H,
NH disappears with D2O), 6.10 (s, 2H, OCH2O), 7.00 (d, J = 8.0, 1H, H5 Ar), 7.14 (dd, J = 8.0, J = 1.6,
1H, H6 Ar), 7.26 (d, J =1.6, 1H, H2 Ar), 7.32–7.52 (m, 6H, 5H Ar + H6), 7.92–8.20 (m, 1H, CH=N), 11.05
(br s, 1H, CONH disappears with D2O). Anal calcd. for C20H17N5O.
(E)-2-Phenyl-N′-(3,4,5-trimethoxybenzylidene)-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-7-carbohydrazide (5h).
Yield 74%. White solid. Mp: 120–121 ◦C. IR (KBr) cm−1: 3400–3200 (NH), 1643 (CONH), 1611 (C=N).
1H-NMR (DMSO-d6): δ 3.60–3.90 (m, 10H, 3OCH3 + H3), 4.60 (n t, 1H, H2), 5.45 (n t, 1H, H3), 6.90–7.00
(s, 2H, Ar), 7.18 (s, 1H, H6) 7.20–7.50 (m, 5H, Ar), 7.90 (br s, 1H, CH=N), 11.10 (br s, 1H, CONH,
disappears with D2O). Anal calcd. for C22H23N5O4.
(E)-N′-(2-(Phenoxy)-3-(methoxy)benzylidene)-2-phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-7-carbo-
hydrazide (5i). Yield 81%. White solid. Mp: 265–266 ◦C. IR (KBr) cm−1: 3261, 3060 (NH), 1629 (CONH),
1580 (C=N). 1H-NMR (DMSO-d6): δ 3.32 (n t, 1 H, H3), 3.62–3.82 (m, 3H, OCH3), 4.60 (n t, 1H, H2), 5.40
(n t, 1H, H3), 6.75–7.60 (m, 13H, Ar), 7.86 (br s, 1H, H6), 8.28 (br s, 2H, CH=N + NH, 1H disappears
with D2O), 11.19 (s, 1H, CONH disappears with D2O). Anal calcd. for C26H23N5O3.
(E)-N′-(2-(Benzyloxy)-3-(methoxy)benzylidene)-2-phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-
7-carbohydrazide (5j). Yield 78%. Light yellow solid. Mp 200–202 ◦C. IR (KBr) cm−1: 3602,
3173 (NH), 1644 (CONH), 1578 (C=N). 1H-NMR (DMSO-d6): δ 3.78–3.96 (m, 4H, OCH3 + H3), 4.61 (n t,
1H, H2), 4.99 (s, 2H, CH2Bz), 5.44 (n t, 1H, H3), 7.00–7.20 and 7.11–7.60 (2 m, 13H, Ar), 7.93 (s, 1H, H6
pyraz.), 8.20–8.50 (br s, 2H, CH=N + NH, 1H disappears with D2O), 11.23 (s, 1H, CONH, disappears
with D2O). Anal calcd. for C27H25N5O3.
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3.2.5. Preparation of (E)-1-acetyl-N′-(3-(cyclopentyloxy)-4-methoxybenzylidene)-2-phenyl-2,3-dihydro-
1H-imidazo[1,2-b]pyrazole-7-carbohydrazide (5k)
A suspension of 5d (0.45 g, 1 mmol) and sodium acetate (0.13 g, 1 mmol) in acetic anhydride
(5 mL) was stirred at 40–50 ◦C for 4 h. After cooling to room temperature, the reaction was poured into
water (20 mL) and extracted with dichloromethane (3 × 10 mL). The organic phase was washed with
brine (3 × 10 mL), dried (MgSO4) and concentrated under reduced pressure to give an oil that was
crystallized by absolute ethanol to give a light yellow solid. Yield: 49%. Mp: 140–141 ◦C. IR (KBr)
cm−1: 2959 (NH), 1650 (C=O), 1596 (C=O). 1H-NMR (CDCl3): δ 1.51–2.20 (m, 8H, 4CH2 cyclopent.),
3.91 (s, 3H, OCH3), 3.97 (s, 3H, CH3CO), 4.15–4.25 (m, 1H, H3), 4.78–5.03 (m, 2H, H2+ CH cyclopent.),
5.78–5.91 (m, 1H, H3), 6.85 (d, J = 10.0, 1H, H5 Ar), 7.00 (dd, J = 10.0, J = 2.0, 1H, H6 Ar), 7.15–7.25
(m, 1H, H2 Ar), 7.35–7.60 (m, 5H, Ar), 8.15 (s, 1H, H6), 8.30 (br s, 1H, CH=N), 9.87 (s, 1H, CONH,
disappears with D2O). Elemental Analysis (%) calculated for C27H29N5O4.
3.3. Biological Studies
3.3.1. Material and Methods
Compounds 4 and 5 were diluted in saline from a stock DMSO solution immediately before
each experiment. 2′,7′-Dichlorofluorescein diacetate (DCFH-DA) and thrombin were purchased from
Sigma-Aldrich/Merck Millipore.
3.3.2. Blood Collection and Preparative Procedures
Freshly drawn venous blood from healthy volunteers of the “Centro Trasfusionale, Ospedale San
Martino” in Genoa was collected into 130 mM aqueous trisodium citrate anticoagulant solution (9:1).
The donors claimed to have not taken drugs known to interfere with platelet function during two
weeks prior to blood collection and gave their informed consent. Washed platelets were prepared
centrifuging whole blood at 100× g for 20 min. The obtained platelet-rich plasma was then centrifuged
at 1100× g for 15 min. Pellet was washed once with pH 5.2 ACD solution (75 mM trisodium citrate, 42
mM citric acid and 136 mM glucose), centrifuged at 1100× g for 15 min and then re-suspended in pH
7.4 Hepes buffer (145 mM NaCl, 5 mM KCl, 1 mM MgSO4, 10 mM glucose, 10 mM HEPES).
3.3.3. ROS Assay
ROS production was quantified as previously reported [22,23] by DCFH-DA, a ROS-sensitive
probe that yields upon oxidation the fluorescent adduct DCF that is trapped inside the cells. Briefly,
washed platelets (1.0 × 108/mL), pre-incubated with saline, compounds 4 or 5, for 15 min at 37 ◦C, were
stimulated by 0.1 U/mL thrombin. Incubation was stopped by cooling samples in ice bath and then
samples were immediately analyzed in a Merck Millipore Bioscience Guava easyCyte flow cytometer
(Merk Millipore, Burlington, MA, USA). The reported IC50 value is the molar concentration of the
compound able to obtain 50% inhibition of the maximal aggregation induced by the agonist and is
calculated by the percentage of inhibition that is the inhibition of the maximal aggregation measured in
the presence of the agent compared with that measured in a control sample containing saline, carried
out under the same conditions.
3.3.4. Platelet Aggregation
Platelet aggregation was performed in a Bio-Data Aggregometer (Bio-Data Corporation, Horsham,
PA, USA) according to Born’s method [39] and quantified by the light transmission reached within
6 min at 37 ◦C. Briefly, washed platelets (3.0 × 108/mL) were pre-incubated for 3 min at 37 ◦C with
saline, compound 4 or 5 before the addition of 0.1 U/mL thrombin. The IC50 values were calculated as
above detailed.
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3.3.5. Isolation of Human Primary Neutrophils
Heparinized (heparin 10 U/mL Vister, PfizerItalia, Borgo San Michele, Latina, Italy) venous blood
was obtained from healthy male volunteers after written informed consent. Neutrophils were isolated
by dextran sedimentation (Dextran 70.000 Plander, Fresenius Kabi Italia, Verona, Italy), and subsequent
centrifugation on a Ficoll-Hypaque density gradient (Lympholyte-I from Cedarlane Laboratories
Ltd. Hornby, ON, Canada), as described [37,40]. Contaminating erythrocytes were removed by
hypotonic lysis. Neutrophils were washed and resuspended in Hanks’balanced salt solution (HBSS;
EuroCLone, Wetherby West, Yorkshire, UK) mixed with Dulbecco’s PBS (EuroClone; HBBS:PBS. Final
cell suspensions contained 97% or more neutrophils and more than 98% viable cells, as evaluated by a
trypan blue test kit (Sigma Aldrich) [38].
3.3.6. Flow Cytometric Assessment of Neutrophil Oxidative Metabolism
Flow cytometric analysis of neutrophil oxidative metabolism was carried out according to
literature method [37]. Briefly, neutrophils, were cultured for 1 h with or without 4d and 5d at different
concentration. Thereafter, neutrophils were pre-treated with 2′-7′-dichlorofluorescein-diacetate
(DCFH-DA; Sigma, Milan, Italy) (5 mM), During the incubation time, DCFH-DA entered into the
cells, and it was cleaved by intracellular esterases to give non-fluorescence DCFH trapped within
the cells. After washing in PBS, the cells were incubated for 15 min at room temperature in the
presence or absence of N-formyl-l-methionin-l-leucyl-l-phenylalanine (fMLP; Sigma, Milan, Italy)
(1 mM) for 30 min at 37 ◦C. During this period, intracellular ROS oxidized DCFH to give a green
fluorescence DCFH. The reaction was stopped by keeping the samples on ice before being analyzed by
flow cytometry (FC500, Beckman Coulter).
In the same test, cell vitality in presence of 4d (10 µM) was assessed by propidium iodide (PI)
method [40–42] at the end of the incubation time. In detail, in the same tubes we added PI staining
solution (10 µg/mL, Invitrogen ThermoFisher Scientific, Waltham, MA, USA) to detect dead cells.
PI is excited at 488 nm and, emits at a maximum wavelength of 617 nm. Because of these spectral
characteristics, PI can be used in combination with other fluorochromes excited at 488 nm such as
fluorescein isothiocyanate (FITC). Auto-fluorescence levels of sample were measured and subtracted
from each analysis. Data were expressed as mean fluorescence intensity ((MFI), compared with the
expression on cells stimulated with control medium alone (defined as 100%)).
3.3.7. Enzymatic Assays
PDE4 tests were performed by Scottish Biomedical Drug Discovery (Scottish, Biomedical Drug
Discovery, Glasgow, UK) using human recombinant enzyme obtained from Spodoptera frugiperda (Sf9)
cells using a baculovirus expression system (PDE enzyme at 0.5 U/mL in 20 mM Tris.HCl pH 7.4) as
previously reported [8,43]. IMAP technology is based on the high affinity binding of phosphate by
immobilized metal coordination complexes on nanoparticles. The binding reagent complexes with
phosphate groups on nucleotide monophosphate generated from cyclic nucleotides (10 mM cAMP)
through phosphodiesterases. With fluorescence polarisation detection, binding causes a change in
the rate of the molecular motion of the phosphate bearing molecule, and results in an increase in the
fluorescence polarization value observed for the fluorescent label attached to the substrate.
Title compounds 4d and 5d were solved in DMSO at 10−2 M concentration and then diluted with
water to the final suitable concentrations. All our subsequent assays were performed in 3% DMSO
(final). All the compounds were tested preliminary at 10 µM concentration, in duplicate.
In all the experiments, Rolipram as reference compound (at 10 µM for PDE4B2 and 1 µM for
PDE4D3) was tested at nine concentrations, in duplicate, to obtain an inhibition curve in order to
validate this experiment.
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Being inhibition >50%, 4d and 5d have been further tested in the same assay at five different
concentrations (5 × 10−8–10−4 M) and IC50 values were determined by nonlinear regression analysis of
the inhibition curve, using Hill equation curve fitting (Graph Pad Prism software, version 5.0a).
4. Conclusions
Starting from previous anti-inflammatory pyrazole and imidazopyrazole scaffolds and PDE4Is,
we designed and synthesized a series of hybrid molecules in order to obtain new antiinflammatory
agents able to act on different biological targets. Preliminary tests evidenced a great antioxidant activity
in neutrophils for compounds 4d and 5d. In addition, the same derivatives showed a good PDE4
inhibition, and also against PDE4B, isoform most involved in inflammation. Results strongly suggested
that the PDE4 inhibition is related to antioxidant activity in neutrophils [15]. In addition, the block of
ROS production on human platelets, that produce high levels of ROS upon thrombin stimulation by
a PDE4-independent mechanism, confirmed that most of tested compounds, except the non-hybrid
intermediates, are able to exert an antioxidant response by two independent mechanisms. Interestingly,
both heterocycle scaffolds (pyrazole and imidazopyrazole) and the substituted catechol moiety, were
determinant for the pharmacodynamic properties. In particular, hybrid molecules bearing to the
pyrazole series were more active than the imidazopyrazole ones, confirming that this part is involved
in the target interaction. In addition, SAR analyses evidenced a clear relationship between the catechol
substituents and the activity.
In conclusion, the hybridization between pyrazole and imidazopyrazole scaffolds and substituted
catechol ring through an acylhydrazone linker, gave a new series of multitarget antiinflammatory
compounds, characterized by a strong antioxidant activity in different biological system.
Supplementary Materials: The following are available online. Figure S1. 1H-NMR spectrum of compound 5a,
Table S1: Elemental analysis of compounds 4a–k, 5a–k, 7, 9, 10, 12.
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Abbreviations
AD Alzheimer’s Disease
COPD Chronic obstructive pulmonary disease
fMLP Formyl-methyl-leucyl-phenylalanine
IL-1 Interleukin 1
IL-8 Interleukine-8
MS Multiple Sclerosis
p38 MAPK p38 Mitogen-Activated Protein Kinase
PDE4 Phosphodiesterase type 4
PDE4Is Phosphodiesterase type 4 Inhibitors
PDGF Platelet derived growth factor
ROS Reactive oxygen species
SAR Structure-activity-relationship
TGF Tumor growth factor
TNFα Tumor necrosis factor alpha
Molecules 2020, 25, 899 16 of 18
References
1. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem.
2005, 48, 6523–6543. [CrossRef]
2. Keith, C.T.; Borisy, A.A.; Stockwell, B.R. Multicomponent therapeutics for networked system. Nat. Rev. Drug
Discov. 2005, 4, 1–7. [CrossRef] [PubMed]
3. Bruno, O.; Brullo, C.; Bondavalli, F.; Schenone, S.; Ranise, A.; Arduino, N.; Bertolotto, M.B.;
Montecucco, F.; Ottonello, L.; Dallegri, F.; et al. Synthesis and biological evaluation of
N-pyrazolyl-N’-alkyl/benzyl/phenylureas: A new class of potent inhibitors of interleukin 8-induced
neutrophil chemotaxis. J. Med. Chem. 2007, 50, 3618–3626. [CrossRef] [PubMed]
4. Bruno, O.; Brullo, C.; Bondavalli, F.; Ranise, A.; Schenone, S.; Falzarano, M.S.; Varani, K.; Spisani, S.
2-Phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives: New potent inhibitors of fMLP-OMe-induced
neutrophil chemotaxis. Bioorg. Med. Chem. Lett. 2007, 17, 3696–3701. [CrossRef] [PubMed]
5. Bruno, O.; Brullo, C.; Bondavalli, F.; Schenone, S.; Spisani, S.; Falzarano, M.S.; Varani, K.;
Barocelli, E.; Ballabeni, V.; Giorgio, C.; et al. 1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/
phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis
inhibitors. Bioorg. Med. Chem. 2009, 17, 3379–3387. [CrossRef]
6. Brullo, C.; Spisani, S.; Selvatici, R.; Bruno, O. N-Aryl-2-phenyl-2,3-dihydro-imidazo[1,2-b]pyrazole-
1-carboxamides 7-substituted strongly inhibiting both fMLP-OMe- and IL-8-induced human neutrophil
chemotaxis. Eur. J. Med. Chem. 2012, 47, 573–579. [CrossRef]
7. Selvatici, R.; Brullo, C.; Bruno, O.; Spisani, S. Differential inhibition of signaling pathways by two new
imidazo-pyrazoles molecules in fMLF-OMe- and IL8-stimulated human neutrophil. Eur. J. Pharm. 2013, 718,
428–434. [CrossRef]
8. Brullo, C.; Ricciarelli, R.; Prickaerts, J.; Arancio, O.; Massa, M.; Rotolo, C.; Romussi, A.;
Rebosio, C.; Marengo, B.; Pronzato, M.A.; et al. New insights into selective PDE4D inhibitors:
3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) oxime (GEBR-7b)
structural development and promising activities to restore memory impairment. Eur. J. Med. Chem. 2016,
124, 82–102. [CrossRef] [PubMed]
9. Ricciarelli, R.; Brullo, C.; Prickaerts, J.; Arancio, O.; Villa, C.; Rebosio, C.; Calcagno, E.; Balbi, M.; Van
Hagen, B.T.J.; Argyrousi, E.K.; et al. Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding
promise for the treatment of Alzheimer’s disease. Sc. Rep. 2017, 7, 46320. [CrossRef]
10. Bruno, O.; Fedele, E.; Prickaerts, J.; Parker, L.A.; Canepa, E.; Brullo, C.; Cavallero, V.; Gardella, E.; Balbi, A.;
Domenicotti, C.; et al. GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at
non-emetic doses. Br. J. Pharmacol. 2011, 164, 2054–2063. [CrossRef]
11. Schafer, P.H.; Parton, A.; Capone, L.; Cedzik, D.; Evans, J.F.; Man, H.V.; Muller, G.W.; Stirling, D.I.; Chopra, L.
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell. Signal. 2014, 26,
2016–2029. [CrossRef] [PubMed]
12. Puhan, M. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst.
Rev. 2011, 8, ED000028.
13. Rabe, K.F.; Bateman, E.D.; O’Donnell, D.; Witte, S.; Bredenbröker, D.; Bethke, T.D. Roflumilast-an oral
anti-inflammatory treatment for chronic obstructive pulmonary disease: A randomised controlled trial.
Lancet 2005, 366, 563–571. [CrossRef]
14. Wang, C.; Wang, Z.; Li, M.; Li, C.; Yu, H.; Zhou, D.; Chen, Z. Reducing neuroinflammation in psychiatric
disorders: Novel target of phosphodiesterase 4 (PDE4) and developing of the PDE4 inhibitors. Mech.
Neuroinflamm. 2017, 3–23.
15. Bruno, O.; Brullo, C.; Arduino, N.; Schenone, S.; Ranise, A.; Bondavalli, F.; Ottonello, L.; Dapino, P.; Dallegri, F.
Synthesis and biological evaluation of neutrophilic inflammation inhibitors. Il Farmaco 2004, 59, 223–235.
[CrossRef] [PubMed]
16. Kümmerle, A.E.; Schmitt, M.; Cardozo, S.V.; Lugnier, C.; Villa, P.; Lopes, A.B.; Romeiro, N.C.; Justiniano, H.;
Martins, M.A.; Fraga, C.A.; et al. Design, synthesis, and pharmacological evaluation of N-acylhydrazones
and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4
inhibitors. J. Med. Chem. 2012, 55, 7525–7545. [CrossRef] [PubMed]
Molecules 2020, 25, 899 17 of 18
17. Hansson, G.K.; Libby, P.; Tabas, I. Inflammation and plaque vulnerability. J. Intern. Med. 2015, 278, 483–493.
[CrossRef]
18. Maritim, A.C.; Sanders, R.A.; Watkins, J.B. Diabetes, oxidative stress, and antioxidants. J. Biochem. Mol.
Toxicol. 2003, 17, 24–38. [CrossRef]
19. Chen, X.; Guo, C.; Kong, J. Oxidative stress in neurodegenerative diseases. Neural. Regen. Res. 2012, 7,
376–385.
20. Haigis, M.C.; Yankner, B.A. The aging stress response. Mol. Cell 2010, 40, 333–344. [CrossRef]
21. Marivet, M.C.; Bourguignon, J.J.; Lugnier, C.; Mann, A.; Stoclet, J.C.; Wermuth, C.G. Inhibition of Cyclic
adenosine-3’,5’-monophosphate Phosphodiesterase From Vascular Smooth Muscle by Rolipram Analogues.
J. Med. Chem. 1989, 32, 1450–1457. [CrossRef] [PubMed]
22. Leoncini, G.; Maresca, M.; Colao, C. Oxidative metabolism of human platelets. Biochem. Int. 1991, 25,
647–655. [PubMed]
23. Maresca, M.; Colao, C.; Leoncini, G. Generation of hydrogen peroxide in resting and activated platelets. Cell
Biochem. Funct. 1992, 10, 79–85. [CrossRef] [PubMed]
24. Friestad, G.K. Chiral N’-Acylhydrazones: Versatile Imino Acceptors for Asymmetric Amine Synthesis. Eur.
J. Org. Chem. 2005, 15, 3157–3172. [CrossRef]
25. Kumar, P.; Kadyan, K.; Duhan, M.; Sindhu, J.; Singh, V.; Saharan, B.S. Design, synthesis, conformational
and molecular docking study of some novel acyl hydrazone based molecular hybrids as antimalarial and
antimicrobial agents. Chem. Centr. J. 2017, 11, 115. [CrossRef]
26. Syakaev, V.; Podyachev, S.N.; Buzykin, B.I.; Syakaeva, V.V.; Podyacheva, S.N.; Buzykina, B.I.; Latypova, S.K.;
Habicherb, W.D.; Konovalova, A.I. NMR study of conformation and isomerization of aryl- and hetero
arylaldehyde 4-tert-butylphenoxyacetylhydrazones. J. Mol. Struct. 2006, 788, 55–62. [CrossRef]
27. Hamzi, I.; Barhoumi-Slimi, T.M.; Abidi, R. Synthesis, characterization, and conformational study of
acylhydrazones of α-β unsaturated aldehydes. Heteroat. Chem. 2016, 27, 139–148. [CrossRef]
28. Angelusiu, M.V.; Barbuceanu, S.F.; Draghici, C.; Almajan, G.L. New Cu(II), Co(II), Ni(II) complexes with
aroyl-hydrazone based ligand. Synthesis, spectroscopic characterization and in vitro antibacterial evaluation.
Eur. J. Med. Chem. 2010, 45, 2055–2062. [CrossRef]
29. Stadler, A.M.; Harrowfeld, J. Bis-acyl-aroyl-hydrazones as multidentate ligands. Inorg. Chim. Acta 2009, 362,
4298–4314. [CrossRef]
30. Onnis, V.; Cocco, M.T.; Fadda, R.; Congiu, C. Synthesis and evaluation of anticancer activity of
2-arylamino-6-trifuoromethyl- 3-(hydrazonocarbonyl)pyridines. Bioorg. Med. Chem. 2009, 17, 6158–6165.
[CrossRef]
31. Hernández-Vázqueza, E.; Castañeda-Arriaga, R.; Ramírez-Espinosad, J.; Medina-Campos, O.N.;
Hernández-Luis, F.; Chaverri, J.P.; Estrada-Soto, S. 1,5-Diarylpyrazole and vanillin hybrids: Synthesis,
biological activity and DFT studies. Eur. J. Med. Chem. 2015, 100, 106–118. [CrossRef] [PubMed]
32. Van Dijken, D.J.; Kovarˇícˇek, P.; Ihrig, S.P.; Hecht, S. Acylhydrazones as Widely Tunable Photoswitches. J. Am.
Chem. Soc. 2015, 137, 14982–14999. [CrossRef] [PubMed]
33. Bondavalli, F.; Botta, M.; Bruno, O.; Ciacci, A.; Corelli, F.; Fossa, P.; Lucacchini, A.; Manetti, F.; Martini, C.;
Menozzi, G.; et al. Synthesis, molecular modeling studies, and pharmacological activity of selective A(1)
receptor antagonists. J. Med. Chem. 2002, 45, 4875–4887. [CrossRef] [PubMed]
34. Brullo, C.; Massa, M.; Villa, C.; Ricciarelli, R.; Rivera, D.; Pronzato, M.A.; Fedele, E.; Barocelli, E.; Bertoni, S.;
Flammini, L.; et al. Synthesis, biological activities and pharmacokinetic properties of new fluorinated
derivatives of selective PDE4D inhibitors. Bioorg. Med. Chem. 2015, 23, 3426–3435. [CrossRef]
35. Crowder, J.R.; Glover, E.E.; Grundon, M.F.; Kaempfen, H.X. Bisbenzylisoquinolines. Part IV. The preparation
of diaryl ethers from diaryliodonium salts. J. Chem. Soc. 1963, 4578–4585. [CrossRef]
36. Ashton, M.J.; Cook, D.C.; Fenton, G.; Karlsson, J.A.; Palfreyman, M.N.; Raeburn, D.; Ratcliffe, A.J.; Souness, J.E.;
Thurairatnam, S.; Vicker, N. Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The
synthesis and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues. J. Med. Chem
1994, 37, 1696–1703. [CrossRef]
37. Raffaghello, L.; Bianchi, G.; Bertolotto, M.B.; Montecucco, F.; Busca, A.; Dallegri, F.; Ottonello, L.; Pistoia, V.
Human mesenchymal stem cells inhibit neutrophil apoptosis: A model for neutrophil preservation in the
bone narrow niche. Stem Cells 2008, 26, 151–162. [CrossRef]
Molecules 2020, 25, 899 18 of 18
38. Verzola, D.; Bertolotto, M.B.; Villaggio, B.; Ottonello, L.; Dallegri, F.; Frumento, G.; Berruti, V.; Gandolfo, M.T.;
Garibotto, G.; Deferrari, G. Taurine prevents apoptosis induced by high glucose in human tubule renal cells.
J. Investig. Med. 2002, 50, 443–451. [CrossRef]
39. Born, G.V.R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962, 194,
927–929. [CrossRef]
40. Bertolotto, M.; Contini, P.; Ottonello, L.; Pende, A.; Dallegri, F.; Montecucco, F. Neutrophil migration towards
C5a and CXCL8 is abrogated by non-steroidal anti-inflammatory drugs (NSAIDs) via the inhibition of
different pathways. Br. J. Pharmacol. 2014, 171, 3376–3393. [CrossRef]
41. Bass, D.A.; Parce, J.W.; Dechatelet, L.R.; Szejda, P.; Seeds, M.C.; Thomas, M. Flow cytometric studies of
oxidative product formation by neutrophils: A graded response to membrane stimulation. J. Immunol. 1983,
130, 1910–1917. [PubMed]
42. Ghio, M.; Ottonello, L.; Contini, P.; Amelotti, M.; Mazzei, C.; Indiveri, F.; Puppo, F.; Dallegri, F. Transforming
growth factor-β1 in supernatants from stored red blood cells inhibits neutrophil locomotion. Blood 2003, 102,
1100–1107. [CrossRef] [PubMed]
43. Saldou, N.; Obernolte, R.; Huber, A.; Badcker, P.A.; Wilhelm, R.; Alvarez, R.; Li, B.; Xia, L.; Callan, O.; Su, C.;
et al. Comparison of recombinant human PDE4 isoforms: Interaction with substrate and inhibitors. Cell.
Signal. 1998, 10, 427–440. [CrossRef]
Sample Availability: Samples of the compounds are available from the authors.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
